Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory F Guzauskas

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Journal of the International AIDS Society|September 25, 2023
The long-term impact and value of curative therapy for HIV: a modelling analysisGregory F Guzauskas, Timothy B Hallett
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
THE AUTHORS RESPONDGregory F Guzauskas, Ryan N Hansen
The Journal of Clinical Ethics|May 13, 2006
The duty to re-contact for newly appreciated risk factors: fragile X premutationGregory F Guzauskas, Robert Roger Lebel
CNS Oncology|August 21, 2018
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patientsGregory F Guzauskas, Marc Salzberg, Bruce Cm Wang
Journal of Managed Care & Specialty Pharmacy|July 27, 2016
Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysisMichael A Serbin, Gregory F Guzauskas, David L Veenstra
Annals of Internal Medicine|July 31, 2023
Web Exclusive. Annals On Call - When Might Genomic Screening Be Cost-Effective?Robert M Centor, Gregory F Guzauskas, Josh F Peterson
Genomics|January 24, 2007
tSNP-based identification of allelic loss of gene expression in a patient with a balanced chromosomal rearrangementGregory F Guzauskas, Kennedy Ukadike, Lynn Rimsky, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug TherapyGregory F Guzauskas, Anirban Basu, Josh J Carlson, et al.
Scientific Reports|February 1, 2024
The value-based price of transformative gene therapy for sickle cell disease: a modeling analysisGeorge Morgan, Emily Back, Martin Besser, et al.
Journal of Medical Economics|November 12, 2021
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancerJosh J Carlson, Gregory F Guzauskas, Robert A Dann, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Journal of the International AIDS Society|September 25, 2023
The long-term impact and value of curative therapy for HIV: a modelling analysisGregory F Guzauskas, Timothy B Hallett
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
THE AUTHORS RESPONDGregory F Guzauskas, Ryan N Hansen
The Journal of Clinical Ethics|May 13, 2006
The duty to re-contact for newly appreciated risk factors: fragile X premutationGregory F Guzauskas, Robert Roger Lebel
CNS Oncology|August 21, 2018
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patientsGregory F Guzauskas, Marc Salzberg, Bruce Cm Wang
Journal of Managed Care & Specialty Pharmacy|July 27, 2016
Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysisMichael A Serbin, Gregory F Guzauskas, David L Veenstra
Annals of Internal Medicine|July 31, 2023
Web Exclusive. Annals On Call - When Might Genomic Screening Be Cost-Effective?Robert M Centor, Gregory F Guzauskas, Josh F Peterson
Genomics|January 24, 2007
tSNP-based identification of allelic loss of gene expression in a patient with a balanced chromosomal rearrangementGregory F Guzauskas, Kennedy Ukadike, Lynn Rimsky, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug TherapyGregory F Guzauskas, Anirban Basu, Josh J Carlson, et al.
Scientific Reports|February 1, 2024
The value-based price of transformative gene therapy for sickle cell disease: a modeling analysisGeorge Morgan, Emily Back, Martin Besser, et al.
Journal of Medical Economics|November 12, 2021
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancerJosh J Carlson, Gregory F Guzauskas, Robert A Dann, et al.
Pageof 4